Get the Stockscreener App
57.40
1.87%
-1.105
Biomarin Pharmaceutical Inc stock is traded at $57.40, with a volume of 519.67K.
It is down -1.87% in the last 24 hours and down -2.72% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
See More
Previous Close:
$58.50
Open:
$58.65
24h Volume:
519.67K
Relative Volume:
0.23
Market Cap:
$11.02B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
21.34
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
+0.17%
1M Performance:
-2.72%
6M Performance:
-16.57%
1Y Performance:
-36.20%
1-Day Range:
$57.36
$58.73
1-Week Range:
$57.27
$58.94
52-Week Range:
$52.93
$93.04
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
57.41 | 11.03B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.13 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.42 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.19 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
699.95 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.98 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Will BioMarin Pharmaceutical Inc. Reverse From Oversold ConditionsJuly 2025 Snapshot & Fast Exit Strategy with Risk Control - classian.co.kr
BioMarin stock price target raised to $95 by Bernstein following Inozyme acquisition - Investing.com
2 Reasons to Watch BMRN and 1 to Stay Cautious - Yahoo Finance
Predicting the Next Rule Breaker Buyout - The Motley Fool
BioMarin (BMRN) Posts Strong Q2 Growth, Advances Rare Disease Research - MSN
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Can BioMarin Pharmaceutical Inc. Overcome Bearish SentimentMarket Volume Summary & Long-Term Growth Plans - classian.co.kr
Trendlines Suggest BioMarin Pharmaceutical Inc. May Bottom Out Soon2025 Big Picture & High Conviction Buy Zone Alerts - kangso.co.kr
BioMarin Fights Back After NICE Blocks English Funding For £500K Batten Disease Drug - insights.citeline.com
Trapped Investors in BioMarin Pharmaceutical Inc. Await Breakout Signal2025 Retail Activity & Technical Entry and Exit Alerts - metal.it
U.S. Batten disease experts who lobbied B.C. to reinstate drug had relationships with company - Times Colonist
Evaluating BioMarin Pharmaceutical Inc. with trendline analysis2025 Performance Recap & AI Forecast Swing Trade Picks - Newser
Is BioMarin Pharmaceutical Inc. forming a bottoming baseMarket Performance Report & Verified Short-Term Trading Plans - Newser
BioMarin’s SWOT analysis: rare disease specialist’s stock faces competition, pipeline potential - Investing.com Nigeria
BioMarin’s SWOT analysis: rare disease specialist’s stock faces competition, pipeline potential By Investing.com - Investing.com South Africa
What machine learning models say about BioMarin Pharmaceutical Inc.2025 Support & Resistance & Advanced Technical Signal Analysis - Newser
Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105 - MSN
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know - Yahoo Finance
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know | FinancialContent - FinancialContent
Is BioMarin Pharmaceutical Inc. stock poised for growthJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - Newser
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo Finance
Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharma - Barchart.com
BC consulted U.S. Batten disease experts who had links to drug company - Vancouver Sun
Solid Earnings Reflect BioMarin Pharmaceutical's (NASDAQ:BMRN) Strength As A Business - Yahoo Finance
Can Traders Expect Breakout From BioMarin Pharmaceutical Inc. This WeekJuly 2025 Setups & Stock Timing and Entry Methods - beatles.ru
BioMarin Announces Resignation of Chief Accounting Officer - The Globe and Mail
Skeletal Dysplasia Market Growth Analysis 2025-2030 - GlobeNewswire
Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Refocused, deal-hungry drugmaker BioMarin pushes toward $4 billion revenue target - The Business Journals
Blair William & Co. IL Cuts Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
PNC Financial Services Group Inc. Boosts Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Risk vs reward if holding onto BioMarin Pharmaceutical Inc.Market Ready Picks with Technical Support - Newser
Using portfolio simulators with BioMarin Pharmaceutical Inc. includedFree Capital Protection Trading Strategies - Newser
What does recent volatility data suggest for BioMarin Pharmaceutical Inc.Machine Learning Stock Movement Detector - Newser
Will BioMarin Pharmaceutical Inc. Benefit From Broader Market BounceTrade Timing Strategy With Technical Data Explained - beatles.ru
Using economic indicators to assess BioMarin Pharmaceutical Inc. potentialFree Secure Return Focused Investment Plan - Newser
The Top 12 Companies Hiring in Biopharma Now - BioSpace
One Healthcare Stock to Watch: BioMarin Pharmaceutical (BMRN) - AInvest
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Positive Earnings Growth Hasn't Been Enough to Get BioMarin Pharmaceutical (NASDAQ:BMRN) Shareholders a Favorable Return Over the Last Five Years - 富途牛牛
BioMarin Pharmaceutical Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2025 Earnings Call Transcript - Insider Monkey
BioMarin Pharmaceutical (BMRN) Receives a Buy from Stifel Nicolaus - The Globe and Mail
Biomarin Pharmaceutical shares rise 2.68% premarket after UBS raised its price target to $114. - AInvest
BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results - The Globe and Mail
Backtesting results for BioMarin Pharmaceutical Inc. trading strategiesFree Daily Momentum Screener With Alerts - Newser
BioMarin’s Earnings Call: Growth Amid Challenges - TipRanks
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 (NASDAQ:BMRN) - Seeking Alpha
Research Alert: CFRA Keeps Buy View On Shares Of Biomarin Pharmaceutical Inc. - 富途牛牛
BIOMARIN PHARMACEUTICAL INC SEC 10-Q Report - TradingView
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):